CIK 0001566044
- Non-accelerated filer
- Smaller reporting company
Yarrow Bioscience, Inc.
Sign in to watch- Ticker
- YARW
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 453757789
- Phone
- +1 203-433-7577
- Business address
- 470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
- Former names
- VYNE Therapeutics Inc., Menlo Therapeutics Inc., Menlo Therapeutics, Inc., Tigercat Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 2 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-29 | Remeditex Ventures LLC 10% owner | Conversion · Series A Preferred Stock | −7,150 | 0 | ||
| 2018-01-29 | Remeditex Ventures LLC 10% owner | Conversion · Series B Preferred Stock | −2,351,097 | 0 | ||
| 2018-01-29 | Remeditex Ventures LLC 10% owner | Conversion · Series C Preferred Stock | −821,596 | 0 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion | +2,348,550 | 2,606,982 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion | +324,306 | 359,992 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion | +917,559 | 3,524,541 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion | +126,703 | 486,695 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion · Series B Preferred Stock | −6,335,215 | 0 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion · Series B Preferred Stock | −874,817 | 0 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion · Series C Preferred Stock | −2,475,118 | 0 | ||
| 2018-01-29 | Vivo Capital VIII, LLC 10% owner | Conversion · Series C Preferred Stock | −341,784 | 0 | ||
| 2018-01-29 | Cha Albert Director | Conversion | +2,348,550 | 2,606,982 | ||
| 2018-01-29 | Cha Albert Director | Conversion | +324,306 | 359,992 | ||
| 2018-01-29 | Cha Albert Director | Conversion | +917,559 | 3,524,541 | ||
| 2018-01-29 | Cha Albert Director | Conversion | +126,703 | 486,695 | ||
| 2018-01-29 | Cha Albert Director | Conversion · Series B Preferred Stock | −6,335,215 | 0 | ||
| 2018-01-29 | Cha Albert Director | Conversion · Series B Preferred Stock | −874,817 | 0 | ||
| 2018-01-29 | Cha Albert Director | Conversion · Series C Preferred Stock | −2,475,118 | 0 | ||
| 2018-01-29 | Cha Albert Director | Conversion · Series C Preferred Stock | −341,784 | 0 | ||
| 2018-01-25 | venBio Global Strategic Fund II L.P. 10% owner | Purchase | +265,000 | $17.00 | $4.5M | 265,000 |
Page 21 of 22 · 425 trades